Green Cross Health Limited Ordinary Shares
GXH.NZXHealth Care
Overview Green Cross Health is a provider of primary health care services to communities throughout New Zealand and supports a network of around 360 pharmacies, 41 medical centres, and provides community health care and nursing services to more than 30,500 people throughout New Zealand. History The business was first listed as Beauty Direct Online Ltd in March 2000. In February 2005 shareholders approved the acquisition of the business of Life Pharmacy and a 49% shareholding in 17 companies operating Life Pharmacies and in March 2005 the company changed its name to Life Pharmacy Ltd (NZX: LPL). In May 2008 LPL acquired Care Chemist Ltd and in 2009, the company merged with Pharmacybrands, a group which included Unichem and Amcal pharmacies. In 2010 the company changed its name from Life Pharmacy Limited to Pharmacybrands Limited (NZX: PHB). The 2011 acquisition of Radius Pharmacy, Radius Medical Limited and Radius Medical Solutions Limited marked a transition to becoming a provider of broader healthcare services. Investment in community care specialist Total Care Health Services in 2014 was followed by the change of company name from Pharmacybrands to Green Cross Health (NZX: GXH) to better reflect the full scope of primary health care services the company offers. The acquisition of Access Homehealth, also in 2014, gave Green Cross Health significant presence in the community health care market, with more than 4,000 support workers and nurses. The company continued to extend its presence in medical services, growing the number of practices and patients with the acquisitions of Tucker Consulting, a management services company serving six medical practices and Peak Primary, a group of 12 wholly owned general practice. By mid-2015, the process of pharmacy rebranding started in 2013 was nearing completion, with the retirement of Amcal, Care Chemist and Radius Pharmacy brands in New Zealand and the growing pharmacy network consolidating under the Unichem and Life Pharmacy retail brands across 330 stores. In 2015 Green Cross Health also acquired the remaining 50% shareholding in Total Care Health Services Limited, further enhancing the opportunity for growth in the community health market in Auckland.
Market Data
$1.980
-0.0%$284.8M
14.0x
$0.142
5.92%
+1.4%
Latest Earnings
GXH: Annual Shareholders’ Meeting: Results
14 July 2026
Green Cross Health held its Annual Shareholders' Meeting on 14 July 2026, with all three ordinary resolutions and one special resolution passing with strong shareholder support (>99% in favour). The most notable outcome was shareholder approval of the sale of all shares in Green Cross Health Medical Limited, a significant divestment approved under section 129 of the Companies Act 1993. No financial results or earnings metrics were reported in this announcement. Key points: All four resolutions passed with overwhelming shareholder support, each receiving more than 99% of votes in favour.; Catherine Treneman elected as a new Director with 99.90% shareholder approval.; Andrew Bagnall re-elected as Director with 99.68% shareholder approval.
Recent Announcements
D&O ongoing disclosure
Kenneth Arthur Orr, a director of Green Cross Health Limited, transferred 414,065 ordinary shares from Orrs Pharmacies Limited to Warren Greene Trust and Grey Duck Trust on 13 July 2026 with nil consideration, resulting in a restructuring of his relevant interests across multiple trusts.
GXH: Annual Shareholders’ Meeting: Results
Green Cross Health held its Annual Shareholders' Meeting on 14 July 2026, with all three ordinary resolutions and one special resolution passing with strong shareholder support (>99% in favour). The most notable outcome was shareholder approval of the sale of all shares in Green Cross Health Medical Limited, a significant divestment approved under section 129 of the Companies Act 1993. No financial results or earnings metrics were reported in this announcement. Key points: All four resolutions passed with overwhelming shareholder support, each receiving more than 99% of votes in favour.; Catherine Treneman elected as a new Director with 99.90% shareholder approval.; Andrew Bagnall re-elected as Director with 99.68% shareholder approval.
GXH: Annual Shareholders’ Meeting: Speeches & Presentation
Green Cross Health held its Annual Shareholders' Meeting on July 14, 2026, presenting FY26 results showing revenue growth of 4% to $546.0 million and operating profit of $45.3 million, with a final dividend of 5.5 cents per share declared. The company is proposing to sell its Medical division to Tend Health for an estimated $270 million, with proceeds to be used for debt repayment and shareholder distribution.
Green Cross Health Limited - Annual Shareholders' Meeting
Green Cross Health Limited is holding its Annual Shareholders' Meeting on 14 July 2026 to seek shareholder approval for the sale of its Medical Division to Tend Health for an estimated $270 million. The Board unanimously recommends approval of this special resolution, which would allow Green Cross Health to refocus on its core pharmacy business and repay bank debt with the sale proceeds.
Revised Annual Meeting Date
Green Cross Health Limited (NZX: GXH) has rescheduled its Annual Meeting from 31 July 2026 to earlier in July to combine it with a shareholder meeting to approve the sale of its Medical division to Tend Health, avoiding two consecutive meetings.
Green Cross Health Limited 2026 Annual Report
Green Cross Health delivered a strong FY2026 result with group revenue of $546.0m (up 4.2%) and EBIT of $45.3m (up 17.0%), driven by solid growth in both Pharmacy (+2% revenue, +4% operating profit) and Medical (+8% revenue, +33% operating profit) divisions. Net profit after tax attributable to shareholders rose 27.7% to $20.4m, with EPS of 14.19 cents. A significant strategic development was announced post-year-end with the conditional sale of the Medical division to Tend Health for $270m, enabling the company to refocus on its core pharmacy business. Key points: NPAT attributable to shareholders grew 27.7% to $20.4m, with EPS up 27.5% to 14.19 cents; Medical division delivered standout performance with operating profit up 33% to $26.0m on revenue growth of 8% to $165.8m; Total FY26 dividends of 8.5 cps declared, with final dividend of 5.5 cps to be paid June 2026, up from prior year
Sale of Green Cross Health’s Medical Division
Green Cross Health Limited (NZX: GXH) has agreed to sell its Medical division (The Doctors) to Tend Health for NZ$270 million, subject to shareholder approval at a July meeting and expected completion by end of July 2026. The sale will allow GXH to refocus on its core pharmacy business, with proceeds potentially used for pharmacy growth investment or shareholder returns.
D&O ongoing disclosure
Rachael Maree Newfield, Group CEO of Green Cross Health Limited, acquired 117,455 ordinary shares on 29 May 2026 through vesting of performance share rights, increasing her total holding from 532,070 to 649,525 shares.
Notice of issue of Ordinary Shares
Green Cross Health Limited issued 117,455 ordinary shares on 29 May 2026 through the vesting of Performance Share Rights under its Performance Share Rights Scheme, representing 0.08% of total ordinary shares on issue. The shares were issued at nil consideration and rank equally with existing ordinary shares.
Green Cross Health Full Year Results to 31 March 2026
Green Cross Health (NZX: GXH) delivered a strong full-year result for the twelve months ended 31 March 2026, with Operating Revenue up 4% to $546.0m and EBIT up 17% to $45.3m. Net Profit After Tax Attributable to Shareholders grew 28% to $20.4m, driven by strong Medical division performance (Operating Profit +33%) and steady Pharmacy growth (Operating Profit +4%). The Board declared a final dividend of 5.50 cents per share, and the company is progressing a potential sale of its Medical division alongside the establishment of a new Primary Health Organisation (PHO) from 1 July 2026. Key points: NPAT attributable to shareholders grew 28% to $20.4m, with EPS of 14.2 cents per share; Medical division delivered exceptional 33% Operating Profit growth to $26.0m, driven by government funding uplift and immunisation-linked incentive payments; Group is now net cash positive at $8.6m with a low gearing ratio of 9.4% and strong operating cash flow of $54.6m
Get real-time alerts for GXH
Receive AI-powered earnings summaries and instant notifications when Green Cross Health Limited Ordinary Shares releases results.
Register Free